Xichun Liu1, Elisa Ledet2, Dongying Li1, Ary Dotiwala2, Allie Steinberger2, Allison Feibus3, Jianzhuo Li1, Yanfeng Qi4, Jonathan Silberstein3, Benjamin Lee3, Yan Dong4, Oliver Sartor2, Haitao Zhang5. 1. Department of Pathology, Tulane University School of Medicine, New Orleans, Louisiana; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana. 2. Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana; Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana. 3. Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana. 4. Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana. 5. Department of Pathology, Tulane University School of Medicine, New Orleans, Louisiana; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: hzhang@tulane.edu.
Abstract
PURPOSE: Most prostate cancer mortality can be attributed to metastatic castration resistant prostate cancer, an advanced stage that remains incurable despite recent advances. The AR (androgen receptor) signaling axis remains active in castration resistant prostate cancer. Recent studies suggest that expression of the AR-V (AR splice variant) AR-V7 may underlie resistance to abiraterone and enzalutamide. However, controversy exists over the optimal assay. Our objective was to develop a fast and sensitive assay for AR-Vs in patients. MATERIALS AND METHODS: Two approaches were assessed in this study. The first approach was based on depletion of leukocytes and the second one used RNA purified directly from whole blood preserved in PAXgene® tubes. Transcript expression was analyzed by quantitative reverse transcription-polymerase chain reaction. RESULTS: Through a side-by-side comparison we found that the whole blood approach was suitable to detect AR-Vs. The specificity of the assay was corroborated in a cancer-free cohort. Using the PAXgene assay samples from a cohort of 46 patients with castration resistant prostate cancer were analyzed. Overall, AR-V7 and ARv567es were detected in 67.53% and 29.87% of samples, respectively. Statistical analysis revealed a strong association of AR-V positivity with a history of second line hormonal therapies. CONCLUSIONS: To our knowledge this is the first study to demonstrate that PAXgene preserved whole blood can be used to obtain clinically relevant information regarding the expression of 2 AR-Vs. These data on a castration resistant prostate cancer cohort support a role for AR-Vs in resistance to therapies targeting the AR ligand-binding domain.
PURPOSE: Most prostate cancer mortality can be attributed to metastatic castration resistant prostate cancer, an advanced stage that remains incurable despite recent advances. The AR (androgen receptor) signaling axis remains active in castration resistant prostate cancer. Recent studies suggest that expression of the AR-V (AR splice variant) AR-V7 may underlie resistance to abiraterone and enzalutamide. However, controversy exists over the optimal assay. Our objective was to develop a fast and sensitive assay for AR-Vs in patients. MATERIALS AND METHODS: Two approaches were assessed in this study. The first approach was based on depletion of leukocytes and the second one used RNA purified directly from whole blood preserved in PAXgene® tubes. Transcript expression was analyzed by quantitative reverse transcription-polymerase chain reaction. RESULTS: Through a side-by-side comparison we found that the whole blood approach was suitable to detect AR-Vs. The specificity of the assay was corroborated in a cancer-free cohort. Using the PAXgene assay samples from a cohort of 46 patients with castration resistant prostate cancer were analyzed. Overall, AR-V7 and ARv567es were detected in 67.53% and 29.87% of samples, respectively. Statistical analysis revealed a strong association of AR-V positivity with a history of second line hormonal therapies. CONCLUSIONS: To our knowledge this is the first study to demonstrate that PAXgene preserved whole blood can be used to obtain clinically relevant information regarding the expression of 2 AR-Vs. These data on a castration resistant prostate cancer cohort support a role for AR-Vs in resistance to therapies targeting the AR ligand-binding domain.
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Giuseppe Galletti; Luigi Portella; Scott T Tagawa; Brian J Kirby; Paraskevi Giannakakou; David M Nanus Journal: Mol Diagn Ther Date: 2014-08 Impact factor: 4.074
Authors: Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Liying Yang; James C Lang; Priya Balasubramanian; Kris R Jatana; David Schuller; Amit Agrawal; Maciej Zborowski; Jeffrey J Chalmers Journal: Biotechnol Bioeng Date: 2009-02-01 Impact factor: 4.530
Authors: Chengfei Liu; Cameron M Armstrong; Wei Lou; Alan P Lombard; Vito Cucchiara; Xinwei Gu; Joy C Yang; Nagalakshmi Nadiminty; Chong-Xian Pan; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2017-05-12 Impact factor: 6.261
Authors: Yezi Zhu; Adam Sharp; Courtney M Anderson; John L Silberstein; Maritza Taylor; Changxue Lu; Pei Zhao; Angelo M De Marzo; Emmanuel S Antonarakis; Mindy Wang; Xingyong Wu; Yuling Luo; Nan Su; Daniel Nava Rodrigues; Ines Figueiredo; Jonathan Welti; Emily Park; Xiao-Jun Ma; Ilsa Coleman; Colm Morrissey; Stephen R Plymate; Peter S Nelson; Johann S de Bono; Jun Luo Journal: Eur Urol Date: 2017-09-01 Impact factor: 20.096
Authors: Kristina Stuopelyte; Rasa Sabaliauskaite; Arnas Bakavicius; Benedikta S Haflidadóttir; Tapio Visakorpi; Riina-Minna Väänänen; Chintan Patel; Daniel C Danila; Hans Lilja; Juozas R Lazutka; Albertas Ulys; Feliksas Jankevicius; Sonata Jarmalaite Journal: J Urol Date: 2020-02-18 Impact factor: 7.450
Authors: Emmanuelle Hodara; Gareth Morrison; Alexander Cunha; Daniel Zainfeld; Tong Xu; Yucheng Xu; Paul W Dempsey; Paul C Pagano; Farideh Bischoff; Aditi Khurana; Samuel Koo; Marc Ting; Philip D Cotter; Mathew W Moore; Shelly Gunn; Joshua Usher; Shahrooz Rabizadeh; Peter Danenberg; Kathleen Danenberg; John Carpten; Tanya Dorff; David Quinn; Amir Goldkorn Journal: JCI Insight Date: 2019-03-07
Authors: Scott T Tagawa; Emmanuel S Antonarakis; Ada Gjyrezi; Giuseppe Galletti; Seaho Kim; Daniel Worroll; John Stewart; Atef Zaher; Ted P Szatrowski; Karla V Ballman; Katsuhiro Kita; Shinsuke Tasaki; Yang Bai; Luigi Portella; Brian J Kirby; Fred Saad; Mario A Eisenberger; David M Nanus; Paraskevi Giannakakou Journal: Clin Cancer Res Date: 2018-10-09 Impact factor: 12.531
Authors: Jessica L Christenson; Jane B Trepel; Haythem Y Ali; Sunmin Lee; Joel R Eisner; Edwina S Baskin-Bey; Anthony D Elias; Jennifer K Richer Journal: Horm Cancer Date: 2018-01-16 Impact factor: 3.869
Authors: Jun Luo; Gerhardt Attard; Steven P Balk; Charlotte Bevan; Kerry Burnstein; Laura Cato; Artem Cherkasov; Johann S De Bono; Yan Dong; Allen C Gao; Martin Gleave; Hannelore Heemers; Mayuko Kanayama; Ralf Kittler; Joshua M Lang; Richard J Lee; Christopher J Logothetis; Robert Matusik; Stephen Plymate; Charles L Sawyers; Luke A Selth; Howard Soule; Wayne Tilley; Nancy L Weigel; Amina Zoubeidi; Scott M Dehm; Ganesh V Raj Journal: Eur Urol Date: 2017-12-16 Impact factor: 20.096